1. Godley PA, Taylor M. Renal cell carcinoma. Curr Opin Oncol 2001; 13: 199–203.
2. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8–29.
3. Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2005 г. М., 2007.
4. Janzen NK, Kim HL, Figlin RA et al. Surveilance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am.
5. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289–96.
6. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22 (3): 454–63.
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408–17.
8. Fojo AT, Shen DW, Mickley LA et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922–7.
9. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992; 148: 1247–8.
10. Oliver RTD, Mehta A, Barnett MJ. A phase 2 study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998; 1: 14–20.
11. McDermott DF, Regan MM, Clark JL et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133–41.
12. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127–32.
13. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.
14. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 3: 1287–95.
14. Herrmann E, Brinkmann OA, Bode ME et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with inter-leukin 2, interferon a and 5-fluorouracil. Eur Urol. In press. doi:10.1016/j.eururo.2006.11.003.
15. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–5.
16. Kaelin Jr WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673–82.
17. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028–13.
18. de Paulsen N, Brychzy A, Foumier MC et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 1387–92.
20. Gollob JA, Wilhelm S, Carter C et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392–106.
21. Schwartz G, Dutcher JP, Vogelzang NJ et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002; 21: 24a (abstract no. 91).
22. Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006; 24 (Suppl.): 217s (abstract no. 4502).
23. Motzer RJ, Amato R, Todd M et al. Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99–101.
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427–34.
24. Hudes G, Carducci M, Tomczac P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006; 24 (Suppl.): 2s (abstract no. LBA4).
25. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12.
26. Hurwitz H, Dowlati A, Savage S et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005; 23 (Suppl. 16S): 195s (abstract no. 3012).
27. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24.
28. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516–24.
29. Motzer RJ, Hutson TE, Tomczac P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 2s (abstract no. LBA3).
30. Amato RJ, Misellati A, Khan M et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 224s (abstract no. 4530).
31. Wilhelm S, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Clin Cancer Res 2004; 64: 7099–109.
32. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92 (10): 1855–61.
33. Strumberg D, Richly H, Hilger RA Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23 (5): 965–72.
35. Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006; 24 (Suppl.): 18s (abstract no. 4501).
36. Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 2007; 356: 125–34.
37. Elsen T, Bukowski RM, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 2006; 24 (Suppl): 223s (abstract 4524).
38. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356 (2): 115–24.